CytoSorbents

CTSOPre-clinical

CytoSorbents is a public company (NASDAQ: CTSO) pioneering blood purification to treat life-threatening conditions in intensive care and cardiac surgery. Its core technology uses highly porous polymer beads to adsorb harmful substances from blood, complementing conventional dialysis. While CytoSorb® is commercially available in over 75 countries with a CE mark, the company is actively pursuing FDA approval for its devices in the United States, representing a significant future growth opportunity.

Market Cap

$376.8M

Employees

150+

CTSO · Stock Price

USD 6.00+3.67 (+158.06%)

Historical price data

AI Company Overview

Technology Platform

Proprietary, biocompatible, highly porous polymer bead technology designed for hemoadsorption, capable of removing a broad range of water-insoluble and larger molecules (cytokines, bilirubin, myoglobin, drugs) from whole blood.

Opportunities

The largest near-term opportunity is securing U.S.

FDA approval for CytoSorb® and DrugSorb-ATR®, which would unlock the world's largest healthcare market.

Long-term growth can come from expanding indications within critical care, increasing adoption in cardiac surgery globally, and penetrating the emerging fields of ex-vivo organ perfusion and veterinary medicine.

Risk Factors

The primary risk is regulatory, specifically the failure to obtain FDA marketing authorization in the United States.

Additional risks include the need for more definitive clinical outcome data, challenges in U.S.

commercialization and reimbursement, competition from established therapies, and the ongoing need for capital to fund operations and trials.

Competitive Landscape

CytoSorbents competes with companies like Toray Medical (Toraymyxin), Baxter (oXiris), and Fresenius in the blood purification space. Its differentiation lies in its broad-spectrum polymer bead adsorption technology, which targets cytokines, bilirubin, myoglobin, and specific drugs, positioning it as a multi-purpose tool for clinical instability in the ICU and OR.